PL2275108T3 - Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej - Google Patents
Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonejInfo
- Publication number
- PL2275108T3 PL2275108T3 PL09746569T PL09746569T PL2275108T3 PL 2275108 T3 PL2275108 T3 PL 2275108T3 PL 09746569 T PL09746569 T PL 09746569T PL 09746569 T PL09746569 T PL 09746569T PL 2275108 T3 PL2275108 T3 PL 2275108T3
- Authority
- PL
- Poland
- Prior art keywords
- dpp
- concomitant
- inhibitor
- therapeutic agent
- pharmaceutical preparation
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008127480 | 2008-05-14 | ||
PCT/JP2009/058803 WO2009139362A1 (ja) | 2008-05-14 | 2009-05-12 | Dpp-iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 |
EP09746569.4A EP2275108B1 (en) | 2008-05-14 | 2009-05-12 | Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2275108T3 true PL2275108T3 (pl) | 2015-01-30 |
Family
ID=41318729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09746569T PL2275108T3 (pl) | 2008-05-14 | 2009-05-12 | Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej |
Country Status (15)
Country | Link |
---|---|
US (1) | US8633199B2 (pl) |
EP (1) | EP2275108B1 (pl) |
JP (1) | JP4643760B2 (pl) |
KR (1) | KR101607081B1 (pl) |
CN (1) | CN102026641A (pl) |
AU (1) | AU2009247251B2 (pl) |
BR (1) | BRPI0912607A2 (pl) |
CA (1) | CA2724133C (pl) |
DK (1) | DK2275108T3 (pl) |
ES (1) | ES2507491T3 (pl) |
MX (1) | MX2010012245A (pl) |
PL (1) | PL2275108T3 (pl) |
PT (1) | PT2275108E (pl) |
RU (1) | RU2523552C2 (pl) |
WO (1) | WO2009139362A1 (pl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP3366304B1 (en) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Diabetes therapy |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
TW201412745A (zh) * | 2012-08-28 | 2014-04-01 | Sanwa Kagaku Kenkyusho Co | N-[2-({2-[(2S)-2-氰基吡咯啶-1-基]-2-側氧乙基}胺基)-2-甲基丙基]-2-甲基吡唑并[1,5-a]嘧啶-6-甲醯胺之結晶 |
WO2014051023A1 (ja) * | 2012-09-27 | 2014-04-03 | 株式会社 三和化学研究所 | アナグリプチン含有製剤 |
WO2014051025A1 (ja) * | 2012-09-27 | 2014-04-03 | 株式会社 三和化学研究所 | アナグリプチン含有固形製剤 |
JP6283313B2 (ja) * | 2012-09-27 | 2018-02-21 | 株式会社三和化学研究所 | アナグリプチン含有医薬組成物 |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
JP6283316B2 (ja) * | 2012-10-26 | 2018-02-21 | 株式会社三和化学研究所 | アナグリプチン含有固形製剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080076811A1 (en) * | 2000-01-21 | 2008-03-27 | Bork Balkan | Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents |
DK1741445T3 (da) * | 2000-01-21 | 2013-11-04 | Novartis Ag | Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7078397B2 (en) * | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
KR100998796B1 (ko) | 2003-01-31 | 2010-12-06 | 가부시키가이샤산와카가쿠켄큐쇼 | 디펩티딜 펩티다아제 iv를 저해하는 화합물 |
GT200600008A (es) * | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
US8754032B2 (en) * | 2005-06-03 | 2014-06-17 | Mitsubishi Tanabe Pharma Corporation | Concomitant pharmaceutical agents and use thereof |
GEP20105033B (en) * | 2005-12-28 | 2010-06-25 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
US7478621B2 (en) * | 2006-04-11 | 2009-01-20 | Zf Friedrichshafen Ag | Method of compensating for engine speed overshoot |
-
2009
- 2009-05-12 DK DK09746569.4T patent/DK2275108T3/da active
- 2009-05-12 MX MX2010012245A patent/MX2010012245A/es active IP Right Grant
- 2009-05-12 PL PL09746569T patent/PL2275108T3/pl unknown
- 2009-05-12 PT PT97465694T patent/PT2275108E/pt unknown
- 2009-05-12 KR KR1020107025700A patent/KR101607081B1/ko active IP Right Grant
- 2009-05-12 CN CN2009801172869A patent/CN102026641A/zh active Pending
- 2009-05-12 EP EP09746569.4A patent/EP2275108B1/en not_active Not-in-force
- 2009-05-12 CA CA2724133A patent/CA2724133C/en not_active Expired - Fee Related
- 2009-05-12 US US12/988,541 patent/US8633199B2/en active Active
- 2009-05-12 WO PCT/JP2009/058803 patent/WO2009139362A1/ja active Application Filing
- 2009-05-12 ES ES09746569.4T patent/ES2507491T3/es active Active
- 2009-05-12 JP JP2010511974A patent/JP4643760B2/ja active Active
- 2009-05-12 AU AU2009247251A patent/AU2009247251B2/en not_active Ceased
- 2009-05-12 RU RU2010143817/15A patent/RU2523552C2/ru not_active IP Right Cessation
- 2009-05-12 BR BRPI0912607A patent/BRPI0912607A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPWO2009139362A1 (ja) | 2011-09-22 |
PT2275108E (pt) | 2014-09-30 |
JP4643760B2 (ja) | 2011-03-02 |
BRPI0912607A2 (pt) | 2019-09-17 |
ES2507491T3 (es) | 2014-10-15 |
AU2009247251A1 (en) | 2009-11-19 |
CA2724133C (en) | 2016-07-12 |
WO2009139362A1 (ja) | 2009-11-19 |
KR20110016889A (ko) | 2011-02-18 |
EP2275108A1 (en) | 2011-01-19 |
AU2009247251A2 (en) | 2011-02-10 |
RU2523552C2 (ru) | 2014-07-20 |
MX2010012245A (es) | 2011-04-11 |
RU2010143817A (ru) | 2012-06-20 |
EP2275108B1 (en) | 2014-07-09 |
KR101607081B1 (ko) | 2016-03-29 |
AU2009247251B2 (en) | 2013-07-18 |
US8633199B2 (en) | 2014-01-21 |
CA2724133A1 (en) | 2009-11-19 |
CN102026641A (zh) | 2011-04-20 |
DK2275108T3 (da) | 2014-09-08 |
US20110071166A1 (en) | 2011-03-24 |
EP2275108A4 (en) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2275108T3 (pl) | Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej | |
IL275854A (en) | Pharmaceutical composition and its administration | |
ZA201206062B (en) | Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy | |
IL206952A (en) | History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines | |
IL209267A (en) | Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug | |
IL210589A (en) | C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB | |
IL206080A0 (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
GB0523576D0 (en) | Drug composition and its use in therapy | |
IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
HU0700828D0 (en) | Transdermal pharmaceutical compositions containing tol perisone alone and in combination | |
GB0921803D0 (en) | Drug composition and its use in therapy | |
PL2012805T3 (pl) | Kompozycja lecznicza i jej zastosowanie | |
EP2322207A4 (en) | OXYGEN TRANSMITTING BLOOD SUBSTITUTE AND PHARMACEUTICAL COMPOSITION (VARIANTS) | |
HK1160761A1 (en) | Medicament dispenser and its use | |
GB0919889D0 (en) | Drug composition and its use in therapy | |
PT2117519E (pt) | Composição farmaceutica compreendendo tramadol e cetoprofeno | |
GB0921805D0 (en) | Drug composition and its use in therapy | |
GB0919893D0 (en) | Drug composition and its use in therapy | |
GB0910375D0 (en) | Drug composition and its use in therapy | |
HK1155062A1 (en) | Pharmaceutical composition and combined agent | |
GB0921804D0 (en) | Drug composition and its use in therapy | |
GB0919890D0 (en) | Drug composition and its use in therapy | |
GB0918727D0 (en) | Drug composition and its use in therapy | |
GB0918728D0 (en) | Drug composition and its use in therapy | |
GB0909352D0 (en) | Drug composition and its use in therapy |